Caribou Biosciences, Inc.

CRBU • Biotechnology

$1.57

— 0.00 (0.00%)

Precio actual

ResultadosÚltimo reporte: 30 jun 2026

PERFIL DÉBILDébilConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Perfil histórico débil. La evidencia actual no sostiene una relación riesgo/retorno favorable.

Capitalización

$158.55M

Crecimiento

-8.9%

Flujo de caja

0/5

Tendencia

Negative

Evidencia

Nivel de deuda manejable · 0.22Liquidez saludable · 5.71Tendencia de crecimiento negativaRentabilidad débil

Datos financieros hasta: 30 jun 2026, 12:00 a.m. UTCÚltima actualización de earnings: 30 jun 2026, 12:00 a.m. UTCÚltima actualización del perfil: 14 ago 2026, 12:21 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$1.57

Change0.00%

Shares Out100.99M

Market Cap$158.55M

Enterprise Value$72.89M

52W Range1.38 - 3.54

Beta2.28

P/E-1.53

P/S18.57

P/B1.62

P/FCF-1.66

EV/Sales8.54

Price$1.57

Change0.00%

Shares Out100.99M

Market Cap$158.55M

Enterprise Value$72.89M

52W Range1.38 - 3.54

Beta2.28

P/E-1.53

P/S18.57

P/B1.62

P/FCF-1.66

EV/Sales8.54

EV/EBITDA-0.68

EV/FCF-0.76

Earnings Yield-65.22%

FCF Yield-60.39%

Dividend Yield0.00%

Gross Margin67.34%

Oper. Margin-12.20%

Profit Margin-13.27%

Debt/Eq0.22

Current Ratio5.71

Quick Ratio5.71

Revenue 5Y-8.92%

Target$5.00

Target Upside218.47%

Target Median$5.00

Target Range3.00 - 7.00

Volume1.09M

Avg Volume1.81M

EPS Surprise0.07

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

22/100

Fortaleza financiera

Deuda, caja, estabilidad

76/100

Potencial de crecimiento

Ingresos y expansión

20/100

Atractivo del precio

Barata o cara hoy

57/100

Por qué este puntaje▼

Nivel de deuda manejable · 0.22Liquidez saludable · 5.71Tendencia de crecimiento negativaRentabilidad débil

Analyst view

Analyst sentiment and price target

CRBU

Analyst sentiment

Based on 9 analyst votes · 2026-09-05

100/100

Bullish

Hold

Bearish

Precio objetivo

2026-08-14

Bajo

$3.00

Promedio

$5.00

Mediana

$5.00

Alto

$7.00

Resumen de la compañía

IPO: 7/23/2021

Industria: Biotechnology

P/B i: 1.62

Deuda / Patrimonio i: 0.22

Margen operativo: -1220.49%

Margen neto: -1327.40%

ROE i: -

ROIC: -

Salud financiera

Puntaje15 / 20

Deuda / Patrimonio: 0.22

Ratio corriente: 5.71

Ratio rápido: 5.71

Estado: Good

Transacciones internas

Actividad reciente de ejecutivos e insiders

Kelly Timothy P

Transacción: 02/25/2026

VENTA

Cambio

-6,228

Precio

$1.93

Presentación

02/27/2026

Tipo

VENTA

Albertson Tina M.

Transacción: 02/24/2026

VENTA

Cambio

-1,066

Precio

$1.96

Presentación

02/24/2026

Tipo

VENTA

Khan Ruhi Ahmad

Transacción: 02/24/2026

VENTA

Cambio

-6,938

Precio

$1.96

Presentación

02/24/2026

Tipo

VENTA

Insider	Tipo	Cambio	Precio	Transacción	Presentación
Kelly Timothy P	VENTA	-6,228	$1.93	02/25/2026	02/27/2026
Albertson Tina M.	VENTA	-1,066	$1.96	02/24/2026	02/24/2026
Khan Ruhi Ahmad	VENTA	-6,938	$1.96	02/24/2026	02/24/2026
MCCLUNG BARBARA G	VENTA	-6,938	$1.96	02/24/2026	02/24/2026
Kelly Timothy P	VENTA	-3,147	$1.96	02/24/2026	02/24/2026
Albertson Tina M.	COMPRA	+55,000	Not reported	02/20/2026	02/24/2026
Albertson Tina M.	COMPRA	+247,500	$1.80	02/20/2026	02/24/2026
Khan Ruhi Ahmad	COMPRA	+45,000	Not reported	02/20/2026	02/24/2026
Khan Ruhi Ahmad	COMPRA	+202,500	$1.80	02/20/2026	02/24/2026
MCCLUNG BARBARA G	COMPRA	+202,500	$1.80	02/20/2026	02/24/2026
MCCLUNG BARBARA G	COMPRA	+45,000	Not reported	02/20/2026	02/24/2026
Kelly Timothy P	COMPRA	+45,000	Not reported	02/20/2026	02/24/2026
Kelly Timothy P	COMPRA	+202,500	$1.80	02/20/2026	02/24/2026
Haurwitz Rachel E.	COMPRA	+151,700	Not reported	02/20/2026	02/20/2026
Haurwitz Rachel E.	COMPRA	+682,500	$1.80	02/20/2026	02/20/2026
Ryali Sriram	COMPRA	+55,000	Not reported	02/20/2026	02/20/2026
Ryali Sriram	COMPRA	+247,500	$1.80	02/20/2026	02/20/2026
Braunstein Scott	COMPRA	+45,000	$1.80	02/20/2026	02/20/2026
GUGGENHIME ANDREW	COMPRA	+45,000	$1.80	02/20/2026	02/20/2026
JOHNSON DAVID LEE	COMPRA	+45,000	$1.80	02/20/2026	02/20/2026

Sobre la compañía

Caribou Biosciences, Inc.

Caribou Biosciences, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to pioneering genome-edited allogeneic cell therapies. These cutting-edge treatments are engineered to address both hematologic malignancies (blood cancers) and solid tumors, serving patients across the United States and internationally. Among its primary therapeutic candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy currently undergoing Phase 1 clinical trials for relapsed or refractory B cell non-Hodgkin lymphoma, and CB-011, an allogeneic anti-BCMA CAR-T cell therapy targeting relapsed or refractory multiple myeloma. Caribou Biosciences is additionally developing CB-012, an allogeneic anti-CD371 CAR-T cell therapy for relapsed or refractory acute myeloid leukemia, along with CB-020, an allogeneic CAR-NK cell therapy aimed at solid tumors. The company also maintains a collaborative agreement with AbbVie Manufacturing Management Unlimited Company for the joint advancement of CAR-T cell therapies. Founded in 2011, Caribou Biosciences' headquarters are located in Berkeley, California.

Fuente - Link

Competidores

AARD ALLO ENTA FHTX HUMA IVA OBIO PRLD PYXS TNYA

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

BlackRock Inc. Invests $13.76 Million in Caribou Biosciences, Inc. $CRBU

BlackRock Inc. purchased a new stake in shares of Caribou Biosciences, Inc. (NASDAQ: CRBU) during the quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 7,815,843 shares of the company's stock, valued at approximately $13,756,000. BlackRock Inc. owned about 7.88% of Caribou Biosciences

Defense World

Looking for Earnings Beat? Buy These 5 Top-Ranked Stocks

Top-ranked stocks ALL, W, BILL, TWLO and CRBU are likely to beat on the bottom line in their upcoming releases.

Zacks Investment Research

Brokerages Set Caribou Biosciences, Inc. (NASDAQ:CRBU) Price Target at $7.75

Caribou Biosciences, Inc. (NASDAQ: CRBU - Get Free Report) has been given an average rating of "Moderate Buy" by the five research firms that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, three have issued a buy rating and one has issued a strong buy rating

Defense World

Caribou Biosciences, Inc. (CRBU) Reports Q2 Loss, Lags Revenue Estimates

Caribou Biosciences, Inc. (CRBU) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to a loss of $0.35 per share a year ago.

Zacks Investment Research

Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update

-- ANTLER phase 1 data presented at EHA 2026 reinforce vispa-cel safety, efficacy, and durability are on par with approved autologous CAR-T cell therapies and that vispa-cel has the potential to overcome access barriers for patients with 2L LBCL -- -- CaMMouflage dose escalation phase 1 data presented at EHA 2026 demonstrate single dose of CB-011 produced deep, durable responses in high-risk, late-line BCMA-naïve r/r MM patients; initial dose expansion data in BCMA-naïve and BCMA-exposed patients expected in H2 2026 -- BERKELEY, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today reported financial results for the second quarter of 2026 and provided a business update.

GlobeNewsWire

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-05-07	-0.33	-0.26	0.07
2026-03-05	-0.33	-0.28	0.05
2025-11-12	-0.36	-0.3	0.06
2025-08-12	-0.4	-0.35	0.05
2025-05-08	-0.43	-0.43	0
2025-03-10	-0.4	-0.39	0.01
2024-11-06	-0.44	-0.38	0.06
2024-08-06	-0.45	-0.42	0.03
2024-05-07	-0.39	-0.46	-0.07
2024-03-11	-0.22	-0.39	-0.17
2023-11-07	-0.38	-0.12	0.26
2023-08-08	-0.49	-0.48	0.01